Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jul 8;63(12):1538–1543. doi: 10.1136/ard.2004.024737

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

K Hyrich 1, A Silman 1, K Watson 1, D Symmons 1
PMCID: PMC1754871  PMID: 15242866

Full Text

The Full Text of this article is available as a PDF (90.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrés E., Limbach F-X, Goichot B., Sibilia J. Silent thyroiditis associated with etanercept in rheumatoid arthritis. Ann Rheum Dis. 2002 Jun;61(6):565–565. doi: 10.1136/ard.61.6.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anker Stefan D., Coats Andrew J. S. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002 Dec;86(2-3):123–130. doi: 10.1016/s0167-5273(02)00470-9. [DOI] [PubMed] [Google Scholar]
  3. Aouba A., De Bandt M., Aslangul E., Atkhen N., Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 2003 Jun;42(6):800–802. doi: 10.1093/rheumatology/keg187. [DOI] [PubMed] [Google Scholar]
  4. Baghai M., Osmon D. R., Wolk D. M., Wold L. E., Haidukewych G. J., Matteson E. L. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001 Jun;76(6):653–656. doi: 10.4065/76.6.653. [DOI] [PubMed] [Google Scholar]
  5. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  6. Benz Matthew S., Glaser Joel S., Davis Janet L. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol. 2003 Apr;135(4):551–553. doi: 10.1016/s0002-9394(02)01978-5. [DOI] [PubMed] [Google Scholar]
  7. Berthelot J-M, Glemarec J., Maugars Y., Prost A. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. Rheumatology (Oxford) 2002 Jun;41(6):703–705. doi: 10.1093/rheumatology/41.6.703. [DOI] [PubMed] [Google Scholar]
  8. Bleumink G. S., ter Borg E. J., Ramselaar C. G., Stricker B. H. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001 Nov;40(11):1317–1319. doi: 10.1093/rheumatology/40.11.1317. [DOI] [PubMed] [Google Scholar]
  9. Brand C. A., Rowley M. J., Tait B. D., Muirden K. D., Whittingham S. F. Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features. Ann Rheum Dis. 1992 Feb;51(2):173–176. doi: 10.1136/ard.51.2.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brion P. H., Mittal-Henkle A., Kalunian K. C. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999 Oct 19;131(8):634–634. doi: 10.7326/0003-4819-131-8-199910190-00031. [DOI] [PubMed] [Google Scholar]
  11. Brown S. Lori, Greene Mark H., Gershon Sharon K., Edwards Evelyne T., Braun M. Miles. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 Dec;46(12):3151–3158. doi: 10.1002/art.10679. [DOI] [PubMed] [Google Scholar]
  12. Cairns A. P., Duncan M. K. J., Hinder A. E., Taggart A. J. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002 Nov;61(11):1031–1032. doi: 10.1136/ard.61.11.1031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cairns A. P., Taggart A. J. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J. 2002 Nov;71(2):101–105. [PMC free article] [PubMed] [Google Scholar]
  14. Camussi G., Albano E., Tetta C., Bussolino F. The molecular action of tumor necrosis factor-alpha. Eur J Biochem. 1991 Nov 15;202(1):3–14. doi: 10.1111/j.1432-1033.1991.tb16337.x. [DOI] [PubMed] [Google Scholar]
  15. Caramaschi P., Biasi D., Carletto A., Bambara L. M. Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol. 2003 Jan-Feb;21(1):136–137. [PubMed] [Google Scholar]
  16. Carmona Loreto, Hernández-García César, Vadillo Cristina, Pato Esperanza, Balsa Alejandro, González-Alvaro Isidoro, Belmonte Miguel Angel, Tena Xavier, Sanmartí Raimon, EMECAR Study Group Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Jul;30(7):1436–1439. [PubMed] [Google Scholar]
  17. Carter J. D., Kanik K. S., Valeriano J. Neck mass in a rheumatoid arthritis patient taking etanercept. J Clin Rheumatol. 2000 Apr;6(2):80–81. doi: 10.1097/00124743-200004000-00004. [DOI] [PubMed] [Google Scholar]
  18. Chan A. T. Y., Cleeve V., Daymond T. J. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002 Jan;78(915):47–48. doi: 10.1136/pmj.78.915.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chopra Nagesh, Kirschenbaum Abram E., Widman David. Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol. 2002 Oct;8(5):265–268. doi: 10.1097/00124743-200210000-00007. [DOI] [PubMed] [Google Scholar]
  20. Chung Eugene S., Packer Milton, Lo Kim Hung, Fasanmade Adedigbo A., Willerson James T., Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003 Jun 9;107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2. [DOI] [PubMed] [Google Scholar]
  21. Cohen M. G., Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis. 1987 Nov;46(11):853–858. doi: 10.1136/ard.46.11.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Cunnane Gaye, Warnock Martha, Fye Kenneth H., Daikh David I. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002 Aug;47(4):445–449. doi: 10.1002/art.10535. [DOI] [PubMed] [Google Scholar]
  23. Cursiefen Claus, Grunke Mathias, Dechant Claudia, Antoni Christian, Jünemann Anselm, Holbach Leonard M. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. Am J Ophthalmol. 2002 Aug;134(2):270–271. doi: 10.1016/s0002-9394(02)01499-x. [DOI] [PubMed] [Google Scholar]
  24. Debandt M., Vittecoq O., Descamps V., Le Loët X., Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003 Feb;22(1):56–61. doi: 10.1007/s10067-002-0654-5. [DOI] [PubMed] [Google Scholar]
  25. Derk C. T., DeHoratius R. J. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis. 2003 Apr;62(4):372–372. doi: 10.1136/ard.62.4.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Deswal A., Bozkurt B., Seta Y., Parilti-Eiswirth S., Hayes F. A., Blosch C., Mann D. L. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29;99(25):3224–3226. doi: 10.1161/01.cir.99.25.3224. [DOI] [PubMed] [Google Scholar]
  27. Doran Michele F., Crowson Cynthia S., Pond Gregory R., O'Fallon W. Michael, Gabriel Sherine E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287–2293. doi: 10.1002/art.10524. [DOI] [PubMed] [Google Scholar]
  28. Edwards I. R., Aronson J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255–1259. doi: 10.1016/S0140-6736(00)02799-9. [DOI] [PubMed] [Google Scholar]
  29. Ellerin Todd, Rubin Robert H., Weinblatt Michael E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003 Nov;48(11):3013–3022. doi: 10.1002/art.11301. [DOI] [PubMed] [Google Scholar]
  30. Favalli E. G., Sinigaglia L., Varenna M., Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11(11):753–755. doi: 10.1191/0961203302lu236cr. [DOI] [PubMed] [Google Scholar]
  31. Fitzcharles Mary-Ann, Clayton Denise, Ménard Henri André. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol. 2002 Dec;29(12):2525–2530. [PubMed] [Google Scholar]
  32. Furst Daniel E., Schiff Michael H., Fleischmann Roy M., Strand Vibeke, Birbara Charles A., Compagnone Daniele, Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563–2571. [PubMed] [Google Scholar]
  33. Galaria N. A., Werth V. P., Schumacher H. R. Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000 Aug;27(8):2041–2044. [PubMed] [Google Scholar]
  34. Gardam Michael A., Keystone Edward C., Menzies Richard, Manners Steven, Skamene Emil, Long Richard, Vinh Donald C. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003 Mar;3(3):148–155. doi: 10.1016/s1473-3099(03)00545-0. [DOI] [PubMed] [Google Scholar]
  35. Geborek P., Crnkic M., Petersson I. F., Saxne T., South Swedish Arthritis Treatment Group Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002 Sep;61(9):793–798. doi: 10.1136/ard.61.9.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Gillmore J. D., Lovat L. B., Persey M. R., Pepys M. B., Hawkins P. N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001 Jul 7;358(9275):24–29. doi: 10.1016/S0140-6736(00)05252-1. [DOI] [PubMed] [Google Scholar]
  37. Glück T., Linde H-J, Schölmerich J., Müller-Ladner U., Fiehn C., Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002 Aug;46(8):2255–2257. doi: 10.1002/art.10374. [DOI] [PubMed] [Google Scholar]
  38. Goldman S. A. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20 (Suppl 100):C40–C44. doi: 10.1016/s0149-2918(98)80007-6. [DOI] [PubMed] [Google Scholar]
  39. Gómez-Reino Juan J., Carmona Loreto, Valverde Vicente Rodríguez, Mola Emilio Martín, Montero Maria Dolores, BIOBADASER Group Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003 Aug;48(8):2122–2127. doi: 10.1002/art.11137. [DOI] [PubMed] [Google Scholar]
  40. Hage Chadi A., Wood Karen L., Winer-Muram Helen T., Wilson Stephen J., Sarosi George, Knox Kenneth S. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003 Dec;124(6):2395–2397. doi: 10.1378/chest.124.6.2395. [DOI] [PubMed] [Google Scholar]
  41. Harney S., O'Shea F. D., FitzGerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis. Ann Rheum Dis. 2002 Jul;61(7):653–654. doi: 10.1136/ard.61.7.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Hrycaj P., Korczowska I., Łacki J. K. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 2003 May;42(5):702–703. doi: 10.1093/rheumatology/keg160. [DOI] [PubMed] [Google Scholar]
  43. Jarrett Stephen J., Cunnane Gaye, Conaghan Philip G., Bingham Sarah J., Buch Maya H., Quinn Mark A., Emery Paul. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003 Oct;30(10):2287–2291. [PubMed] [Google Scholar]
  44. Kaneko H., Yamada H., Mizuno S., Udagawa T., Kazumi Y., Sekikawa K., Sugawara I. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest. 1999 Apr;79(4):379–386. [PubMed] [Google Scholar]
  45. Kavanaugh A., St Clair E. W., McCune W. J., Braakman T., Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000 Apr;27(4):841–850. [PubMed] [Google Scholar]
  46. Kent Peter D., Davis John M., 3rd, Davis Mark D. P., Matteson Eric L. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum. 2002 Aug;46(8):2257–2259. doi: 10.1002/art.10348. [DOI] [PubMed] [Google Scholar]
  47. Kessler D. A. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993 Jun 2;269(21):2765–2768. doi: 10.1001/jama.269.21.2765. [DOI] [PubMed] [Google Scholar]
  48. Kindler V., Sappino A. P., Grau G. E., Piguet P. F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989 Mar 10;56(5):731–740. doi: 10.1016/0092-8674(89)90676-4. [DOI] [PubMed] [Google Scholar]
  49. Kremer Joel M., Weinblatt Michael E., Bankhurst Arthur D., Bulpitt Ken J., Fleischmann Roy M., Jackson Christopher G., Atkins Kelly M., Feng Anyang, Burge Daniel J. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003 Jun;48(6):1493–1499. doi: 10.1002/art.11142. [DOI] [PubMed] [Google Scholar]
  50. Kroesen S., Widmer A. F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003 May;42(5):617–621. doi: 10.1093/rheumatology/keg263. [DOI] [PubMed] [Google Scholar]
  51. Kuruvilla John, Leitch Heather A., Vickars Linda M., Galbraith Paul F., Li Charles H., Al-Saab Saad, Naiman Sheldon C. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003 Nov;71(5):396–398. doi: 10.1034/j.1600-0609.2003.00115.x. [DOI] [PubMed] [Google Scholar]
  52. Kwon Hyon J., Coté Timothy R., Cuffe Michael S., Kramer Judith M., Braun M. Miles. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–811. doi: 10.7326/0003-4819-138-10-200305200-00008. [DOI] [PubMed] [Google Scholar]
  53. Lee Jong-Hoon, Slifman Nancy R., Gershon Sharon K., Edwards Evelyne T., Schwieterman William D., Siegel Jeffrey N., Wise Robert P., Brown S. Lori, Udall John N., Jr, Braun M. Miles. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002 Oct;46(10):2565–2570. doi: 10.1002/art.10583. [DOI] [PubMed] [Google Scholar]
  54. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  55. Lock C., Oksenberg J., Steinman L. The role of TNFalpha and lymphotoxin in demyelinating disease. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I121–I128. doi: 10.1136/ard.58.2008.i121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  57. Manadan A. M., Block J. A., Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003 Jul-Aug;21(4):526–526. [PubMed] [Google Scholar]
  58. Marchesoni A., Arreghini M., Panni B., Battafarano N., Uziel L. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. Rheumatology (Oxford) 2003 Jan;42(1):193–194. doi: 10.1093/rheumatology/key051. [DOI] [PubMed] [Google Scholar]
  59. Mayordomo Lucia, Marenco Jose Luis, Gomez-Mateos Jesus, Rejon Eduardo. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol. 2002;31(1):44–45. doi: 10.1080/030097402317255372. [DOI] [PubMed] [Google Scholar]
  60. McCain M. E., Quinet R. J., Davis W. E. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002 Jan;41(1):116–117. doi: 10.1093/rheumatology/41.1.116. [DOI] [PubMed] [Google Scholar]
  61. Misery L., Perrot J. L., Gentil-Perret A., Pallot-Prades B., Cambazard F., Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002 Feb;146(2):334–335. doi: 10.1046/j.1365-2133.2002.4653_4.x. [DOI] [PubMed] [Google Scholar]
  62. Mohan N., Edwards E. T., Cupps T. R., Oliverio P. J., Sandberg G., Crayton H., Richert J. R., Siegel J. N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862–2869. doi: 10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  63. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  64. Nakelchik Masha, Mangino Julie E. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 2002 Jan;112(1):78–78. doi: 10.1016/s0002-9343(01)00945-7. [DOI] [PubMed] [Google Scholar]
  65. Parra Ruiz Jorge, Ortego Centeno Norberto, Raya Alvarez Enrique. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol. 2003 Jul;30(7):1657–1658. [PubMed] [Google Scholar]
  66. Phillips Kristine, Husni M. Elaine, Karlson Elizabeth W., Coblyn Jonathan S. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum. 2002 Feb;47(1):17–21. doi: 10.1002/art1.10243. [DOI] [PubMed] [Google Scholar]
  67. Pincus T., Stein C. M. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997 May-Jun;15 (Suppl 17):S27–S38. [PubMed] [Google Scholar]
  68. Prior P., Symmons D. P., Scott D. L., Brown R., Hawkins C. F. Cause of death in rheumatoid arthritis. Br J Rheumatol. 1984 May;23(2):92–99. doi: 10.1093/rheumatology/23.2.92. [DOI] [PubMed] [Google Scholar]
  69. Rovere Querini P., Vecellio M., Sabbadini M. G., Ciboddo G. Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology (Oxford) 2002 Feb;41(2):231–231. doi: 10.1093/rheumatology/41.2.231. [DOI] [PubMed] [Google Scholar]
  70. Saleem G., Li S. C., MacPherson B. R., Cooper S. M. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum. 2001 Aug;44(8):1966–1968. doi: 10.1002/1529-0131(200108)44:8<1966::AID-ART339>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  71. Sawalha Amr H., Lutz Brock D., Chaudhary Nadeem A., Kern William, Harley John B., Greenfield Ronald A. Panniculitis: a presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol. 2003 Aug;9(4):259–262. doi: 10.1097/01.rhu.0000083606.71931.79. [DOI] [PubMed] [Google Scholar]
  72. Selmaj K. W. Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann Rheum Dis. 2000 Nov;59 (Suppl 1):i94–102. doi: 10.1136/ard.59.suppl_1.i94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Shakoor Najia, Michalska Margaret, Harris Charlotte A., Block Joel A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002 Feb 16;359(9306):579–580. doi: 10.1016/S0140-6736(02)07714-0. [DOI] [PubMed] [Google Scholar]
  74. Shergy William J., Isern Reuben A., Cooley David A., Harshbarger John L., Huffstutter J. Eugene, Hughes Gordon M., Spencer-Smith Elizabeth A., Goldman Allan L., Roth Sanford H., Toder J. Scott. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002 Apr;29(4):667–677. [PubMed] [Google Scholar]
  75. Sicotte N. L., Voskuhl R. R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001 Nov 27;57(10):1885–1888. doi: 10.1212/wnl.57.10.1885. [DOI] [PubMed] [Google Scholar]
  76. Sidiropoulos P., Bertsias G., Kritikos H. D., Kouroumali H., Voudouris K., Boumpas D. T. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis. 2004 Feb;63(2):144–148. doi: 10.1136/ard.2003.015933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Slifman Nancy R., Gershon Sharon K., Lee Jong-Hoon, Edwards Evelyne T., Braun M. Miles. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003 Feb;48(2):319–324. doi: 10.1002/art.10758. [DOI] [PubMed] [Google Scholar]
  78. Smith Davey, Letendre Scott. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med. 2002 Jan 15;136(2):174–174. doi: 10.7326/0003-4819-136-2-200201150-00020. [DOI] [PubMed] [Google Scholar]
  79. Soliotis F., Glover M., Jawad A. S. M. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis. 2002 Sep;61(9):850–851. doi: 10.1136/ard.61.9.850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Solomon Daniel H., Karlson Elizabeth W., Rimm Eric B., Cannuscio Carolyn C., Mandl Lisa A., Manson JoAnn E., Stampfer Meir J., Curhan Gary C. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303–1307. doi: 10.1161/01.cir.0000054612.26458.b2. [DOI] [PubMed] [Google Scholar]
  81. Swale V. J., Perrett C. M., Denton C. P., Black C. M., Rustin M. H. A. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003 Nov;28(6):604–607. doi: 10.1046/j.1365-2230.2003.01411.x. [DOI] [PubMed] [Google Scholar]
  82. Symmons Deborah P. M., Silman Alan J. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 2004 Jun;50(6):1703–1706. doi: 10.1002/art.20312. [DOI] [PubMed] [Google Scholar]
  83. Tai T. L., O'Rourke K. P., McWeeney M., Burke C. M., Sheehan K., Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 2002 Aug;41(8):951–952. doi: 10.1093/rheumatology/41.8.951. [DOI] [PubMed] [Google Scholar]
  84. Taylor J. C., Orkin R., Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford) 2003 Jul;42(7):901–902. doi: 10.1093/rheumatology/keg158. [DOI] [PubMed] [Google Scholar]
  85. Taylor P. C. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 2001 May;13(3):164–169. doi: 10.1097/00002281-200105000-00003. [DOI] [PubMed] [Google Scholar]
  86. Temekonidis T. I., Georgiadis A. N., Alamanos Y., Bougias D. V., Voulgari P. V., Drosos A. A. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis. 2002 Sep;61(9):822–825. doi: 10.1136/ard.61.9.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Torre-Amione G., Kapadia S., Lee J., Durand J. B., Bies R. D., Young J. B., Mann D. L. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996 Feb 15;93(4):704–711. doi: 10.1161/01.cir.93.4.704. [DOI] [PubMed] [Google Scholar]
  88. True David G., Penmetcha Mohan, Peckham Steven J. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol. 2002 Jul;29(7):1561–1563. [PubMed] [Google Scholar]
  89. Vonkeman H. E., van der Valk P. D. L. P. M., Mulder L., van de Laar M. A. F. J. Fatale miliaire tuberculose tijdens behandeling met infliximab. Ned Tijdschr Geneeskd. 2002 Jun 22;146(25):1196–1199. [PubMed] [Google Scholar]
  90. Walsh D. A., Wilson D. Post-mortem collection of human joint tissues for research. Rheumatology (Oxford) 2003 Jun 27;42(12):1556–1558. doi: 10.1093/rheumatology/keg406. [DOI] [PubMed] [Google Scholar]
  91. Watson Douglas J., Rhodes Thomas, Guess Harry A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003 Jun;30(6):1196–1202. [PubMed] [Google Scholar]
  92. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  93. Weinblatt Michael E., Keystone Edward C., Furst Daniel E., Moreland Larry W., Weisman Michael H., Birbara Charles A., Teoh Leah A., Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45. doi: 10.1002/art.10697. [DOI] [PubMed] [Google Scholar]
  94. Wood Karen L., Hage Chadi A., Knox Kenneth S., Kleiman Martin B., Sannuti Aruna, Day Richard B., Wheat L. Joseph, Twigg Homer L., 3rd Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003 Feb 13;167(9):1279–1282. doi: 10.1164/rccm.200206-563OC. [DOI] [PubMed] [Google Scholar]
  95. Wooten M. D., Reddy G. V., Johnson R. D. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000 Dec;72(12):517–519. [PubMed] [Google Scholar]
  96. Yun J. E., Lee S. W., Kim T. H., Jun J. B., Jung S., Bae S. C., Kim T. Y., Yoo D. H. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002 Mar-Apr;20(2):127–132. [PubMed] [Google Scholar]
  97. de' Clari Franco, Salani I., Safwan E., Giannacco A. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation. 2002 May 28;105(21):E183–E183. doi: 10.1161/01.cir.0000017216.41471.df. [DOI] [PubMed] [Google Scholar]
  98. ten Tusscher Marcel P. M., Jacobs Piet J. C., Busch Michiel J. W. M., de Graaf Linda, Diemont Willem L. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ. 2003 Mar 15;326(7389):579–579. doi: 10.1136/bmj.326.7389.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. van der Klooster J. M., Bosman R. J., Oudemans-van Straaten H. M., van der Spoel J. I., Wester J. P. J., Zandstra D. F. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003 Nov 5;29(12):2327–2329. doi: 10.1007/s00134-003-1867-z. [DOI] [PubMed] [Google Scholar]
  100. van der Laken C. J., Lems W. F., van Soesbergen R. M., van der Sande J. J., Dijkmans B. A. C. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum. 2003 Jan;48(1):269–270. doi: 10.1002/art.10629. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES